Paxlovid magani ne na bincike da ake amfani da shi don kula da COVID-19 mai sauƙi zuwa matsakaici a cikin manya da yara [shekaru 12 da haihuwa suna yin awo aƙalla kilo 88 (kg 40)] tare da ingantaccen sakamako na gwajin hoto na SARS-CoV-2 kai tsaye, kuma waɗanda ke cikin babban haɗarin ci gaba zuwa mummunan COVID-19, gami da asibiti ko mutuwa. Paxlovid yana bincike saboda har yanzu ana nazarinsa. Akwai iyakataccen bayani game da aminci da ingancin amfani da Paxlovid don kula da mutanen da ke da COVID-19 mai sauƙi zuwa matsakaici.
FDA ta ba da izinin yin amfani da gaggawa na Paxlovid don kula da COVID-19 mai sauƙi-zuwa-matsakaici a cikin manya da yara [shekaru 12 da haihuwa suna yin awo aƙalla kilo 88 (kg 40)] tare da ingantaccen gwajin cutar yana haifar da COVID-19, kuma waɗanda ke cikin haɗarin ci gaba zuwa matsananciyar COVID-19, gami da asibiti ko mutuwa, ƙarƙashin EUA.

Paxlovid ba magani ba ne da FDA ta amince da shi a cikin Amurka. Yi magana da mai ba da lafiyar ku game da zaɓuɓɓukanku ko kuma idan kuna da wasu tambayoyi. Zaɓin ku ne ku ɗauki Paxlovid.

Paxlovid ya ƙunshi magunguna guda biyu: nirmatrelvir da ritonavir.

Nirmatrelvir [PF-07321332] shine mai hana SARS-CoV-2 babban protease (Mpro) mai hanawa (wanda kuma aka sani da SARS-CoV2 3CL protease inhibitor) wanda ke aiki ta hanyar hana kwafin kwayar cuta a farkon matakan cutar don hana ci gaba zuwa mummunan COVID- 19.

Ana amfani da Ritonavir tare da nirmartrelvir don taimakawa rage karfin metabolism don ya ci gaba da aiki a cikin jiki na tsawon lokaci a mafi girma taro don taimakawa wajen magance cutar.